In yesterday’s Wall Street session, Helius Medical Technologies Inc. (NASDAQ:HSDT) shares traded at $0.26, up 23.26% from the previous session.
As of this writing, 3 analysts cover Helius Medical Technologies Inc. (NASDAQ:HSDT). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $5.00 and a low of $1.00, we find $3.50. Given the previous closing price of $0.22, this indicates a potential upside of 1490.91 percent. HSDT stock price is now -3.18% away from the 50-day moving average and -78.24% away from the 200-day moving average. The market capitalization of the company currently stands at $8.00M.
There are 0 analysts who have given it a hold rating, whereas 3 have given it a buy rating. Brokers who have rated the stock have averaged $3.17 as their price target over the next twelve months.
With the price target of $20, Noble Capital Markets recently initiated with Outperform rating for Helius Medical Technologies Inc. (NASDAQ: HSDT).
In other news, ANDREEFF DANE, President and CEO bought 80,041 shares of the company’s stock on Dec 16. The stock was bought for $19,946 at an average price of $0.25. Upon completion of the transaction, the President and CEO now directly owns 332,517 shares in the company, valued at $86454.42. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 23, President and CEO ANDREEFF DANE bought 89,300 shares of the business’s stock. A total of $27,835 was incurred on buying the stock at an average price of $0.31. This leaves the insider owning 308,003 shares of the company worth $80080.78. A total of 4.01% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in HSDT stock. A new stake in Helius Medical Technologies Inc. shares was purchased by NORTHERN TRUST CORP during the first quarter worth $6,000. TWO SIGMA SECURITIES, LLC invested $5,000 in shares of HSDT during the first quarter. In the first quarter, PRIVATE ADVISOR GROUP, LLC acquired a new stake in Helius Medical Technologies Inc. valued at approximately $4,000. SPIRE WEALTH MANAGEMENT acquired a new stake in HSDT for approximately $1,000. In total, there are 26 active investors with 5.20% ownership of the company’s stock.
Wednesday morning saw Helius Medical Technologies Inc. (NASDAQ: HSDT) opened at $0.2100. During the past 12 months, Helius Medical Technologies Inc. has had a low of $0.21 and a high of $5.79. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 15.20, and a quick ratio of 14.70. The fifty day moving average price for HSDT is $0.2737 and a two-hundred day moving average price translates $1.2179 for the stock.
The latest earnings results from Helius Medical Technologies Inc. (NASDAQ: HSDT) was released for Jun, 2022. According to the Medical Devices Company, earnings per share came in at -$0.97, beating analysts’ expectations of -$1.12 by 0.15. This compares to -$2.01 EPS in the same period last year. The company reported revenue of $0.2 million for the quarter, compared to $0.11 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 79.82 percent. For the current quarter, analysts expect HSDT to generate $170k in revenue.
Helius Medical Technologies Inc.(HSDT) Company Profile
Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-invasive technologies for the treatment of symptoms caused by neurological disease or trauma. Its product, Portable Neuromodulation Stimulator (PoNS), is a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company is headquartered in Newtown, Pennsylvania.